
FOXO TECHNOLOGIES INC.
100
Recent developments highlight FOXO's expansion of wound care services at Big South Fork Medical Center, establishment of an acquisition corporation for strategic growth, and ongoing acquisition agreements to broaden its healthcare services footprint.
- FOXO Technologies Inc. expanded wound care services at Big South Fork Medical Center in Oneida, Tennessee, enhancing clinical offerings [N7].
- The company established FOXO Acquisition Corporation to support strategic growth initiatives in healthcare services [N8].
- FOXO entered a non-binding acquisition agreement to acquire Vector BioSource Inc., expanding its life science services segment [N8].
- The company announced a non-binding acquisition agreement for two assisted living facilities in Florida, indicating diversification in healthcare services [N8].
FOXO Technologies Inc. operates four synergistic divisions focused on healthcare services and technology: a rural hospital division, a mental and behavioral health division, an information, data and biospecimen sourcing division, and an epigenetics diagnostics and interpretation division. The company manages three reportable segments: Healthcare (including Myrtle Recovery Centers and Big South Fork Medical Center), Life Science Services (Vector BioSource Inc.), and Labs (epigenetic biomarker technology commercialization). FOXO's Healthcare segment provides behavioral health and critical access hospital services primarily in rural Tennessee. The Life Science Services segment supports biotechnology and pharmaceutical research with biological materials and data. The Labs segment develops saliva-based epigenetic biomarker technology for underwriting and wellness applications, holding patents and exploring commercialization. FOXO faces complex healthcare regulations and has undergone multiple reverse stock splits due to stock price pressures. The company has significant indebtedness and liquidity challenges, with a controlling shareholder concentration. Recent strategic activities include expansion of wound care services, establishment of an acquisition corporation, and pending acquisitions subject to regulatory approvals and financing.
FOXO Technologies Inc. is a diversified healthcare services and technology company operating in behavioral health, rural hospital services, life science sourcing, and epigenetics diagnostics. The company manages three segments: Healthcare, Life Science Services, and Labs. It has expanded clinical capabilities and services at its hospital and behavioral health centers and is pursuing acquisitions to grow its footprint. FOXO faces significant regulatory requirements typical of healthcare providers and has substantial indebtedness raising going concern doubts. The company has executed multiple reverse stock splits to maintain compliance and address stock price challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, FOXO reported $7.0 million in revenue and $101,301 in net income, with liquidity ratios indicating a current ratio of 0.1 and cash ratio of 0.
FOXO's integrated healthcare and life sciences platform leverages synergies across behavioral health, rural hospital services, and biological sourcing. Expansion of clinical capabilities and wound care services at its hospital and behavioral health centers demonstrate operational progress. The company's proprietary epigenetic biomarker technology, supported by patents and machine learning, positions it for innovative underwriting and wellness applications. Strategic acquisitions and establishment of an acquisition corporation indicate growth initiatives. If regulatory approvals and financing are secured, FOXO's diversified model could enhance its market presence and service offerings.
FOXO faces substantial risks including significant indebtedness with many promissory notes in default, raising going concern doubts. Multiple reverse stock splits reflect sustained downward pressure on stock price and liquidity challenges. The Strategic Technology License Agreement limits FOXO's control and economic upside of its epigenetics intellectual property. Pending acquisitions require regulatory approvals and additional financing, with uncertain completion. Concentrated control by a majority shareholder may limit minority stockholder influence. Regulatory compliance complexity and capital constraints pose ongoing operational risks. These factors collectively challenge FOXO's financial stability and growth prospects.
FOXO's moat derives from its diversified healthcare services portfolio combining rural hospital operations, behavioral health treatment centers, life science sourcing capabilities, and proprietary epigenetic biomarker technology. The company's critical access hospital designation and licensed behavioral health facilities provide essential services in underserved rural markets, creating barriers to entry. Its Life Science Services segment benefits from established biological material sourcing networks supporting clinical research. The Labs segment's proprietary epigenetic biomarker technology, supported by patents and machine learning applications, offers potential differentiation in underwriting and wellness testing. However, the company's moat is challenged by regulatory complexity, capital constraints, and competitive pressures in healthcare and biotechnology sectors.
• Financial and Liquidity Risks: FOXO has significant and increasing indebtedness, including senior unsecured notes in default accruing penalties, raising substantial doubt about its ability to continue as a going concern. Liquidity ratios as of September 30, 2026, indicate a current ratio of 0.1 and cash ratio of 0, reflecting tight liquidity.
• Stock Price and Market Risks: The company has executed multiple reverse stock splits since April 2025 due to sustained downward pressure on its stock price. The Class A Common Stock trades on the OTC market after delisting from NYSE American, with an unapproved Nasdaq listing application, limiting liquidity and investor interest.
• Regulatory and Compliance Risks: FOXO operates in a heavily regulated healthcare environment subject to Certificate of Need requirements, utilization review, EMTALA, drug dispensing licenses, and fraud and abuse laws. Non-compliance could result in penalties, loss of program participation, or reputational damage.
• Intellectual Property and Control Risks: The Strategic Technology License Agreement grants exclusive commercialization rights and an option to acquire majority ownership of FOXO Labs to an entity controlled by the founder, limiting FOXO's control and economic benefits from its epigenetics intellectual property. This agreement presents potential conflicts of interest.
• Acquisition and Integration Risks: Pending acquisitions, including blood collection center assets from Grifols and assisted living facilities, require regulatory approvals and additional financing. Failure to close or integrate these acquisitions successfully could adversely affect operations and financial condition.
• Governance and Concentration Risks: Rennova Health, Inc., controlled by FOXO's CEO, holds approximately 99.12% of voting power, concentrating control and potentially limiting the influence of other stockholders on corporate matters.
Business trends: Expansion of healthcare services including wound care and acquisitions in behavioral health and life sciences; ongoing development of epigenetic biomarker technology.
Execution milestones: Completion of pending acquisitions subject to regulatory approvals and financing; successful integration of new facilities; progress in commercialization of epigenetics segment.
Key risks: Substantial indebtedness and liquidity constraints raising going concern doubts; regulatory compliance complexity; limitations on control and economic benefits from intellectual property licensing; concentrated shareholder control.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- FOXO Technologies Inc. is a healthcare services and technology company operating four synergistic divisions: rural hospital, mental and behavioral health, information/data/biospecimen sourcing, and epigenetics diagnostics and interpretation [S1].
- The company manages three reportable segments: Healthcare (including Myrtle Recovery Centers, Rennova Community Health, and Scott County Community Health), Life Science Services (Vector BioSource Inc.), and Labs (epigenetics biomarker technology commercialization) [S1].
- Myrtle Recovery Centers provides behavioral health services including substance use disorder treatment on inpatient, residential, and outpatient bases, operating in rural markets [S1].
- Rennova Community Health operates Big South Fork Medical Center, a 25-bed Critical Access Hospital in Oneida, Tennessee, offering emergency and ancillary services; it expanded clinical capabilities with tele-specialty and cardiac diagnostics in January 2026 [S1].
- Vector BioSource Inc. sources and distributes biological materials and data services to pharmaceutical and biotechnology research sectors, supporting clinical trials and research [S1].
- The Labs segment focuses on epigenetic biomarker technology for underwriting risk classification in life insurance, using saliva-based biomarkers and machine learning; it holds patents and is exploring commercialization and strategic alternatives [S1].
- The company faces complex healthcare regulations including Certificate of Need requirements, utilization review, EMTALA, drug dispensing licenses, and fraud and abuse laws [S1].
- FOXO Technologies has undergone multiple reverse stock splits between April 2025 and June 2026 to maintain compliance and address stock price issues [S2].
- The company has significant indebtedness including senior unsecured notes with restrictive covenants, raising substantial doubt about its ability to continue as a going concern [S2].
- FOXO Labs entered a Strategic Technology License Agreement in May 2026 granting exclusive commercialization rights and an option to acquire majority ownership to an entity controlled by the founder, limiting FOXO's control and economic upside [S2].
- The company has a pending acquisition agreement for blood collection center assets from Grifols requiring regulatory approvals and additional financing, with closing conditions outside FOXO's control [S2].
- FOXO's Class A Common Stock is quoted on the OTC market after delisting from NYSE American in August 2025; the company has applied for Nasdaq listing but has not been approved [S2].
- Rennova Health, Inc., controlled by FOXO's CEO, holds approximately 99.12% of voting power, concentrating control and potentially limiting influence of other stockholders [S2].
- As of September 30, 2026, FOXO reported cash and equivalents of $42,678, current assets of $4,049,755, current liabilities of $39,817,932, revenue of $7,003,778, and net income of $101,301; liquidity ratios indicate a current ratio of 0.1 and cash ratio of 0 [S2].
- Recent business developments include expansion of wound care services at Big South Fork Medical Center and establishment of FOXO Acquisition Corporation for strategic growth in healthcare services [N7][N8].
- FOXO has entered non-binding acquisition agreements for Vector BioSource Inc. and two assisted living facilities in Florida [N8].
Generated 2026-11-16
- S1 | 2026-04-15 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-16 | www.nasdaq.com | Rising Indian Sugar Production Weighs on Prices | https://www.nasdaq.com/articles/rising-indian-sugar-production-weighs-prices
- N2 | 2026-11-16 | www.nasdaq.com | ProShares Ultra S&P500 (SSO) Shares Cross Below 200 DMA | https://www.nasdaq.com/articles/proshares-ultra-sp500-sso-shares-cross-below-200-dma
- N3 | 2026-11-16 | www.nasdaq.com | Invesco S&P 500 Equal Weight Industrials (RSPN) Shares Cross Below 200 DMA | https://www.nasdaq.com/articles/invesco-sp-500-equal-weight-industrials-rspn-shares-cross-below-200-dma
- N4 | 2026-11-16 | www.nasdaq.com | Arabica Coffee Settles Higher as ICE Inventories Dwindle | https://www.nasdaq.com/articles/arabica-coffee-settles-higher-ice-inventories-dwindle
- N5 | 2026-11-16 | www.nasdaq.com | Cocoa Prices Fall on Abundant Supplies | https://www.nasdaq.com/articles/cocoa-prices-fall-abundant-supplies
- N6 | 2026-11-16 | www.nasdaq.com | Cotton Facing Monday Weakness | https://www.nasdaq.com/articles/cotton-facing-monday-weakness
- N7 | 2025-06-17 | www.nasdaq.com | FOXO Technologies Inc. Expands Wound Care Services at Big South Fork Medical Center in Oneida, Tennessee | https://www.nasdaq.com/articles/foxo-technologies-inc-expands-wound-care-services-big-south-fork-medical-center-oneida
- N8 | 2025-06-16 | www.nasdaq.com | FOXO Technologies Inc. Establishes FOXO Acquisition Corporation for Strategic Growth in Healthcare Services | https://www.nasdaq.com/articles/foxo-technologies-inc-establishes-foxo-acquisition-corporation-strategic-growth-healthcare
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


